Pavmed Inc (PAVM) Stock Price, Quote & News

Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precance...

Industry: Medical Devices

Sector: Healthcare

Phone: (917) 813-1828

Website: www.pavmed.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

DEEZNUTTS2112 Oct. 6 at 8:38 PM

$PAVM one day we will pull an SPRB

0 · Reply

quegoalasoche Oct. 6 at 7:58 PM

$PAVM lets go! Tik tok.

0 · Reply

DEEZNUTTS2112 Oct. 6 at 7:12 PM

$PAVM here we go

0 · Reply

dmc4321 Oct. 6 at 3:02 PM

This is WRONG. $LUCD is a trade its not an investment. Why? Wall Street institutions are filled with experienced traders looking for any and every advantage. They are backed up by support staff that read and analyze EVERY SEC filing, and model EVERYTHING for EVERY diagnostic company. Then they back test it. We forecast this would happen, did it?, what did we miss, should we change our model. Rinse and repeat. So you must believe you and other retail investors in $LUCD or, $PAVM most of which do not even read the SEC filings, know more? Take BTIG's 2027 DCF Price Target of $2.50 for LUCD. BTIG's compliance department said the maximum value you can give to LUCD is $247.5 Million based on our internal models. So the analyst at the very end said its based on 99M shares being outstanding, even though there are 230M shares outstanding. Why not say 100M shares? because that would have exceeded their Model based on EVERY diagnostic test launch EVER and would have to be justified.

1 · Reply

peepthestamp Oct. 6 at 2:35 PM

$PMNT $PAVM $PMN $RVPH $ACET

0 · Reply

builderup Oct. 6 at 3:48 AM

Here we go! Let’s make $ $QNCX $SURG $IBRX $PAVM

1 · Reply

ESignalExpert Oct. 5 at 4:25 PM

$PAVM Biotech speculation. Pre-revenue stage. Chart shows high risk/reward. No pattern recognition.

0 · Reply

Dapperbob Oct. 4 at 3:38 AM

$PAVM I remember when this was mid 9s a few years ago and I rode from 1s to that. Since then I have accumulated a very hefty bit of cake. I however have reserved a notable amount to buy back into this when things look bright. Love all you aklog longs. May we all die rich.

0 · Reply

MichaelJOreuh Oct. 3 at 12:00 PM

$PAVM $LUCD yes, I agree with you here. Free shares are never a good look when you're making bank off of investors. Another sign of toxicity from management.

1 · Reply

LPlates Oct. 3 at 1:30 AM

$PAVM you have got to look at how much of their own money they have put in. Literally besides Acklog through a 3rd party vehicle, they are all WAY LESS than even 1 months salary. When I first investigated $PAVM one of the things I thought, and stated NUMEROUS times, was that Lishan and Dennis etc were aligned with Retail Shareholders. I can say that has changed COMPLETELY. All their upside is on continuing to suck $PAVM & $LUCD dry through their monthly salary's. How can you justify at all Lishans Dennis taking $360K EACH out of PAVM plus another $360K each out of LUCD. PAVM has less than $10K in ANNUAL Revenue, & will have to delist in January or do a SECOND 15 to 1 REVERSE SPLIT yet these clowns 🤡🤡 are taking $720K out🤑🤑. They have SQUANDERED more than $500M.. Just check the Press Release going back two or three years. Write down what based on the press release what it guided you to expect to happen, and then see what actually happened. They are playing retail.

0 · Reply

Market Cap	9.55M
Revenue (ttm)	3.00M
Net Income (ttm)	39.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,326.33%
Debt to Equity Ratio	0.00

Volume	246,400
Avg Vol	252,286
Day's Range	N/A - N/A
Shares Out	21.93M
Stochastic %K	72%
Beta	1.07
Analysts	Sell
Price Target	$10.50